What Thymosin Alpha-1 is and how it was discovered
Thymosin Alpha-1 (Ta1) is a 28-amino-acid peptide, one of several biologically active fragments isolated from calf thymus tissue by Allan Goldstein's group in the 1970s. The full purification and amino acid sequence were published in the Proceedings of the National Academy of Sciences in 1977 (Goldstein et al., Proc Natl Acad Sci, 1977). The molecule has an acetylated serine at its N-terminus and no internal disulfide bonds, which makes it heat-stable and less prone to the aggregation problems seen in larger, structurally complex peptides.
The synthetic version, thymalfasin, has been marketed as Zadaxin since the 1990s by SciClone Pharmaceuticals. It holds approval in more than 35 countries, mostly in Asia, the Middle East, and Latin America, for chronic hepatitis B, chronic hepatitis C in combination with interferon, and as a general immune adjuvant. Thymalfasin has never been approved by the FDA in the United States, where it is available only through research suppliers or compounding pharmacies.
Mechanism: toll-like receptor signaling and dendritic cell maturation
Ta1 does not bind one dedicated receptor. It engages toll-like receptors on antigen-presenting cells, chiefly TLR2, TLR4, and TLR9, triggering MyD88-dependent signaling that activates NF-kB and p38 MAPK. A 2004 study by Romani and colleagues at the University of Perugia, published in Blood, traced this to dendritic cells specifically: Ta1 primed them for a Th1-biased antifungal response through TLR9 signaling, raising interleukin-12 output and steering T-cell differentiation toward Th1 (Romani et al., Blood, 2004).
Downstream of receptor engagement, Ta1 accelerates dendritic cell maturation and increases natural killer cell cytotoxicity. It also raises CD4+ and CD8+ T-lymphocyte counts in models of immunosuppression and chronic infection. The receptor-level action is broad rather than pathway-specific, which is why the compound turns up in research on viral hepatitis, sepsis, vaccine response, and transplant infection rather than one narrow indication.
Thymosin Alpha-1 research: what the clinical trials show
The strongest human data comes from chronic hepatitis B. Chien and colleagues at Chang Gung Memorial Hospital in Taiwan randomized 98 patients into three groups: a 26-week course of Ta1 (1.6 mg subcutaneously, twice weekly), a 52-week course of the same regimen, and an 18-month untreated control group. Complete virologic response, meaning clearance of both HBV DNA and HBeAg, reached 40.6% in the 26-week arm and 26.5% in the 52-week arm, against 9.4% in controls (Chien et al., Hepatology, 1998, n=98).
A separate trial in transplant medicine tested Ta1 against cytomegalovirus infection complicated by acute respiratory distress syndrome after kidney transplantation. Of 46 patients, the 32 who received Ta1 had a rescue success rate of 78.1%, against 50.0% in the 14 untreated controls, and CD4+ lymphocyte counts rose significantly by day 14 in the treated group (Ji et al., Transplant Proc, 2007, n=46).
Sepsis is where the record gets complicated. The 2013 ETASS trial randomized 361 ICU patients with severe sepsis across six hospitals in China. Twenty-eight-day mortality was 28.7% in the Ta1 group against 39.4% in controls, a relative risk of 0.73 (Wu et al., Crit Care, 2013, n=361). That result held up across several later meta-analyses and helped justify a larger confirmatory trial.
The TESTS trial, published in 2025, enrolled 1,106 adults with sepsis across 22 centers in China and found no mortality benefit: 28-day all-cause mortality was 23.4% with Ta1 against 24.1% with placebo, a hazard ratio of 0.99 that did not reach significance (BMJ, 2025, n=1106). The gap between the earlier single-blind trial and the later double-blind, adequately powered one is worth noting. A positive result in a smaller trial does not guarantee it survives a properly controlled follow-up at ten times the size.
Vaccine adjuvant research predates most of the above. Gravenstein and colleagues ran a double-blind, placebo-controlled trial giving Ta1 (900 mcg/m2 subcutaneously, twice weekly for eight doses) alongside the 1986 trivalent influenza vaccine to 90 men aged 65 to 99, with usable serum from 85 of them. Antibody response at six weeks was significantly greater in the Ta1 group (p=.023), and the effect was concentrated in the oldest, least responsive subjects (Gravenstein et al., J Am Geriatr Soc, 1989, n=85).
Pharmacokinetic work has been done separately from the efficacy trials. A crossover study in nine healthy male volunteers compared three commercial Ta1 formulations, Zadaxin, Timosina, and Tal-HLR, after a subcutaneous dose of 900 mcg/m2. All three reached peak plasma concentration within 1 to 2 hours, with a terminal half-life close to 2 hours and no meaningful accumulation across repeated dosing (Rost et al., Int J Clin Pharmacol Ther, 1999, n=9).
Practical considerations for research handling
Ta1 is supplied lyophilized and reconstituted with bacteriostatic water, following the same general rules as other small research peptides. The reconstitution guide covers gentle mixing to avoid denaturation, diluent volume for a target concentration, and syringe technique. Because the trials above used exact mcg or mg dosing on a fixed schedule, researchers replicating a published protocol should check the concentration math with the dosing calculator instead of estimating by eye.
Reconstituted Ta1, like other peptides without disulfide bonds, holds up reasonably well, but it still degrades faster at room temperature than under refrigeration. The general handling window described in the lyophilized peptide storage guide applies here as it does to the rest of the catalog.
Sourcing Thymosin Alpha-1 research material in Indonesia
Indonesia's humidity and ambient heat make the storage advice above more than a formality. Lyophilized peptide vials shipped to Bali, Jakarta, or other Indonesian cities should go into refrigeration on arrival rather than sit at room temperature through a tropical afternoon. Under BPOM's framework for research and laboratory materials, thymosin alpha-1 supplied for research use is handled as a laboratory reagent, a different regulatory category from the clinical thymalfasin product sold as Zadaxin in some Asian markets. Researchers should keep that distinction in mind when reading regulatory summaries that blend the two together.
How Thymosin Alpha-1 compares to other thymic peptides
Thymosin Alpha-1 is sometimes confused with Thymosin Beta-4 and its synthetic fragment TB-500, but the two belong to unrelated peptide families with different mechanisms. Ta1 works through toll-like receptor signaling on immune cells, while Thymosin Beta-4 and TB-500 work through actin sequestration and cell migration in tissue repair. The mechanism and evidence base for that peptide are covered in the TB-500 and thymosin beta-4 research overview.
Both peptide families are listed together in the thymosin peptide catalog, since the shared name invites mix-ups that the underlying biology does not support.